Malignant Neoplastic Disease clinical trials at UC Irvine

• Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

  open to eligible people ages 18 years and up

  This study will evaluate the safety, tolerability, drug levels, molecular effects, and clinical activity of MRTX849 in patients with advanced solid tumors that have a KRAS G12C mutation.

  Orange, California and other locations

Last updated: April 29, 2020